Reverse epidemiology reflects C-reactive protein as a bystander of atherosclerosis in established systemic inflammation models

International Journal of Cardiology

Volumn 146, Issue 3, 2011, Pages 422-423

  Lin, Gen Min ^a   Chu, Kai Min ^b   Han, Chih Lu ^c  

^a HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Atherosclerosis; C reactive protein; Reverse epidemiology

Indexed keywords

C REACTIVE PROTEIN; MATRIX METALLOPROTEINASE; PLACEBO; ROSUVASTATIN; TURPENTINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CULTURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME SYNTHESIS; HUMAN; INFLAMMATION; LETTER; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 78951478528     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.094     Document Type: Article

References (12)

1. C.J. Lavie, R.V. Milani, and H.O. Ventura Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss J Am Coll Cardiol 53 2009 1925 1932
2. K. Kalantar-Zadeh, G. Block, and T. Howich Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure J Am Coll Cardiol 43 2004 1439 1444
3. S. Beddhu, N. Ramkumar, and M.H. Samore The paradox of the "body mass index paradox" in dialysis patients: associations of adiposity with inflammation Am J Clin Nutr 82 2005 909 910
4. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
5. R.J. Glynn, W. Koenig, and B.G. Nordestgaard Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial Ann Intern Med 152 2010 488 496
6. S. Mora, R.J. Glynn, and J. Hsia Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
7. R.J. Bisoendial, S.M. Boekholdt, and M. Vergeer C-reactive protein is a mediator of cardiovascular disease Eur Heart J 31 2010 2087 2091
8. A. Paul, K.W. Ko, and L. Li C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice Circulation 109 2004 647 655
9. G.A. Tennent, W.L. Hutchinson, and M.C. Kahan Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice Atherosclerosis 196 2008 248 255
10. A. Kovacs, P. Tornvall, and R. Nilsson Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia Proc Natl Acad Sci USA 104 2007 13768 13773
11. T. Koike, S. Kitajima, and Y. Yu Human C-reactive protein does not promote atherosclerosis in transgenic rabbits Circulation 120 2009 2088 2094
12. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150